• Patricia Midori Murobushi Ozawa, Tayana Schultz Jucoski, Evelyn Vieira, Tamyres Mingorance Carvalho, Danielle Malheiros, and Enilze Maria de Souza Fonseca Ribeiro.
• Postgraduate Program in Genetics, Genetics Department, Federal University of Parana, Curitiba, Parana, Brazil.
• Transl Res. 2020 Sep 1; 223: 40-60.

AbstractImprovement of breast cancer (BC) patient's outcome is directly related to early detection. However, there is still a lack of reliable biomarkers for diagnosis, prognosis and, treatment follow up in BC, leading researchers to study the potential of liquid biopsy based on circulating microRNAs (c-miRNAs). These c-miRNAs can be cell-free or associated with extracellular vesicles (EVs), and have great advantages such as stability in biofluids, noninvasive accessibility compared to current techniques (core-biopsy and surgery), and expression associated with pathogenic conditions. Recently, a new promising field of EV-derived miRNAs (EV-miRNAs) as cancer biomarkers has emerged, receiving special attention due to their selective vesicle sorting which makes them accurate for disease detection. In this review, we discuss new findings about c-miRNA and their potential as biomarkers for BC diagnosis, prognosis, and therapy. Additionally, we address the impact of limitations associated with the standardization of analysis techniques and methods on the implementation of these biomarkers in the clinical setting.Copyright © 2020 Elsevier Inc. All rights reserved.

15 keywords...

hide…